The most-studied growth hormone secretagogue combination: a GHRH analog (CJC-1295) paired with a selective GHRP (Ipamorelin). Together they trigger an amplified GH pulse that neither produces alone. Here's what the published research actually shows.
CJC-1295 and Ipamorelin act on completely different receptors — that's the entire basis of the stack. Together they hit both the GHRH axis and the ghrelin axis simultaneously, producing a supra-additive GH response.
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the hypothalamic peptide that instructs the pituitary to produce GH. It binds to GHRH receptors (GHRH-R) on anterior pituitary somatotrophs, triggering cAMP signaling and GH vesicle release — exactly the same pathway used by endogenous GHRH.
Ipamorelin (NNC-26-0161) is a pentapeptide growth hormone secretagogue and ghrelin receptor agonist (GHS-R1a). It binds to a completely different receptor than GHRH analogs, stimulating GH release through a distinct second messenger cascade involving IP3/DAG signaling and calcium mobilization.
Somatostatin (SRIF) is the hypothalamic "brake" on GH release. GHRH analogs amplify GH production while somatostatin holds the gates closed. Ipamorelin and other GHRPs work partly by suppressing this somatostatin tone — which is a key reason why combining both classes works so powerfully.
Like sermorelin, secretagogue-driven GH is still governed by somatostatin negative feedback. The hypothalamus can still attenuate the response when GH/IGF-1 levels rise — providing a built-in safeguard not present with exogenous HGH injection.
The pituitary has two pools of GH vesicles: a readily releasable pool (RRP) and a reserve pool. GHRH analogs primarily refill the RRP over time, while GHRPs trigger acute release from the RRP. When dosed together, CJC-1295 primes the pituitary and Ipamorelin triggers the release event — amplifying the pulse height.
Most GHRPs (GHRP-2, GHRP-6, hexarelin) also raise cortisol, prolactin, and ACTH at effective doses. Ipamorelin is unique: Raun et al. (1998) showed it produced robust GH release in rat models without significantly elevating these hormones, even at doses much higher than those required for GH release.
The combination of a GHRH analog with a GHRP is a well-characterized pharmacological interaction in the GH axis research literature. The two peptide classes act at different receptor subtypes and through different intracellular pathways — producing an effect greater than the sum of their parts.
GHRH-R agonist
cAMP pathway
Primes somatotrophs
Refills GH reserve
GHS-R1a agonist
IP3/Ca²⁺ pathway
Suppresses SRIF
Triggers acute release
Dual-pathway activation produces a substantially larger and more sustained GH pulse than either peptide alone. The GHRH analog ensures a well-primed pituitary with full GH reserves; the GHRP triggers a strong, clean release event without cortisol/prolactin co-elevation.
Research basis: The synergy between GHRH analogs and GHRPs in GH secretion has been documented in multiple pharmacological studies. A review by Sinha et al. (PMC7108996) notes that the combination of a GHRH analog with a GH secretagogue is the most physiologically appropriate approach to stimulating GH in adults, because it recapitulates the dual-signal mechanism that underlies endogenous pulsatile GH secretion during sleep.
The reason growth hormone secretion is pulsatile in the first place is that endogenous GHRH and somatostatin alternate in their dominance — creating peaks and troughs. GHRPs add a third signal by activating the ghrelin receptor, which further suppresses somatostatin during the trough phase. The net result: injecting CJC-1295 (to prime) and Ipamorelin (to trigger) just before the natural nocturnal GH pulse window (approximately 30–60 minutes after sleep onset) is designed to amplify the pulse that would have occurred anyway.
The landmark pharmacokinetic and pharmacodynamic study of CJC-1295 (with Drug Affinity Complex) was conducted by Teichman and colleagues and published in the Journal of Clinical Endocrinology & Metabolism in 2006. It remains the most-cited human clinical data on CJC-1295. PMID: 16882835.
Study design (Teichman 2006): 57 healthy adults (ages 21–61), randomized double-blind placebo-controlled, single subcutaneous injection of CJC-1295 (with DAC) at doses of 30, 60, 90, or 120 mcg/kg. Serial GH and IGF-1 measurements were taken over 28 days post-injection. The study demonstrated dose-dependent, sustained GH and IGF-1 elevation with a single injection — a pharmacokinetic profile not seen with any prior GH secretagogue.
Raun et al. published the foundational characterization of ipamorelin in 1998, demonstrating that it is the most selective GH secretagogue identified at that time. PMID: 9849822.
Cross-trial caveat: The GHRP comparison data above comes from in vivo rat model studies (Raun 1998). Direct head-to-head human comparisons of ipamorelin vs. GHRP-6 vs. hexarelin at equivalent GH-producing doses in humans are limited. The selectivity advantage of ipamorelin over other GHRPs is well-supported by preclinical data, and no clinical study has demonstrated meaningful cortisol elevation with ipamorelin at standard research doses.
CJC-1295 comes in two fundamentally different versions with different half-lives, dosing frequencies, and pharmacodynamic profiles. The clinical Teichman 2006 study used CJC-1295 WITH DAC (the long-acting version). In practice, the two are used very differently.
Naming confusion: "CJC-1295" is often used generically by vendors to refer to Modified GRF 1-29 (without DAC), even though the Teichman 2006 study used CJC-1295 WITH DAC. When ordering or researching, always confirm which version is being discussed. The no-DAC version (Mod GRF 1-29) is most commonly paired with Ipamorelin in pre-bed dosing protocols because its short half-life creates a discrete pulse rather than sustained GH elevation.
The following dosing information reflects the protocols described in published literature and commonly used in research settings. This is not medical advice. All peptide use should be supervised by a qualified healthcare provider.
Important: CJC-1295 and Ipamorelin are not FDA-approved for anti-aging, body composition, or performance use. They are available as research compounds and, in some jurisdictions, as compounded medications via prescription. Dosing guidance here is derived from published research protocols and clinical practice patterns — not FDA-approved labeling. Consult a healthcare provider before use.
How the CJC/Ipa stack compares to other common approaches to growth hormone optimization. Note that direct head-to-head human trials are limited — comparisons rely on independent study data and pharmacological reasoning.
| Parameter | CJC-1295 / Ipamorelin | Sermorelin | MK-677 | Exogenous HGH |
|---|---|---|---|---|
| Mechanism | GHRH-R + GHS-R1a (dual) | GHRH-R only | GHS-R1a (oral) | Direct GH replacement |
| GH pattern | Pulsatile (amplified) | Pulsatile (natural amplitude) | Sustained elevation | Flat-line ("square wave") |
| Pituitary required? | Yes | Yes | Yes | No — bypasses pituitary |
| Feedback-regulated? | Yes | Yes | Partial | No |
| Cortisol elevation | Minimal (ipamorelin selective) | None | Reported in some studies | None |
| Water retention | Mild (dose-dependent) | Mild | Often significant (~1-3 kg) | Significant, common |
| Dosing frequency | Daily (Mod GRF) or weekly (DAC) | Daily injections | Once daily oral | Daily injections (IU-dosed) |
| Cost (relative) | Low–moderate | Low–moderate | Low (oral) | High ($500–3000/month) |
| IGF-1 elevation | Moderate–significant | Moderate | ~40% above baseline (Murphy 1998) | Significant (dose-dependent) |
| Human RCT data? | CJC-1295 DAC: yes (Teichman 2006); Mod GRF: limited | Yes (Khorram 1997) | Yes (Murphy 1998) | Extensive |
| FDA status | Not approved | Compounded (was approved 1997–2008) | Not approved (research) | Approved for specific indications |
| Legal prescribing | Off-label compound, jurisdiction-dependent | Compounded, off-label legal | Research/grey market | Heavily restricted (federal law) |
The following protocol structures reflect what is described in research and clinical practice contexts for the CJC-1295 + Ipamorelin stack. Protocol selection depends on which form of CJC-1295 is used. All peptide use should be supervised by a qualified healthcare provider.
| Peptide | Dose | Frequency | Timing |
|---|---|---|---|
| CJC-1295 (with DAC) | 1–2 mg | Once weekly | Evening, fasted |
| Ipamorelin | 200–300 mcg | 1–3× daily | Before bed and/or fasted morning |
| Peptide | Dose | Frequency | Timing |
|---|---|---|---|
| CJC-1295 (no DAC / Mod GRF 1-29) | 100 mcg | 1–3× daily | Before bed and/or fasted morning |
| Ipamorelin | 200–300 mcg | 1–3× daily | Matched to CJC timing (same injection) |
Timing science: The body's largest natural GH pulse occurs roughly 60–90 minutes after falling asleep. Dosing 30 minutes before bed on an empty stomach is designed to amplify this pulse — adding secretagogue stimulus to the pituitary just before the natural release window opens. Carbohydrates and elevated insulin significantly blunt the GH response — always dose fasted, at least 2–3 hours after the last meal. Morning dosing on an empty stomach adds a secondary daytime pulse when the body is naturally in a low-insulin fasted state.
Standard approach: 8–12 weeks on, followed by a 4-week off period. Some practitioners use a 5-days-on / 2-days-off pattern within the active cycle to limit receptor accommodation. The 4-week break allows GHRH receptor sensitivity to reset before the next cycle begins.
Test IGF-1 at three checkpoints: at baseline before starting, again at 4 weeks into the cycle, and at cycle end. Target the upper-normal physiological range. If IGF-1 climbs supraphysiological (above ~300 ng/mL for most adults), reduce dose or pause. IGF-1 is the primary safety signal for GH axis protocols.
From a licensed compounding pharmacy, the CJC-1295 + Ipamorelin stack typically runs $100–250 per month depending on dose, form, and pharmacy. Research chemical vendors may charge less but with variable quality standards.
From the Teichman 2006 data, a single CJC-1295 DAC injection elevated GH by 2–10× for at least 6 days and raised IGF-1 by 1.5–3× for 9–11 days. With ongoing multi-dose protocols, sustained IGF-1 elevation was maintained without tachyphylaxis — response did not diminish with repeated dosing, a key finding distinguishing CJC-1295 from earlier GHRH compounds.
Sleep quality typically shifts first — deeper sleep architecture, more vivid dreaming. GH pulses are incrementally increasing with each dose. Mild flushing or warmth immediately post-injection is a normal acute response. No visible body composition changes expected this early.
Recovery between training sessions begins to improve. Skin texture changes are sometimes noticed. IGF-1 should now be measurably above baseline on a blood test. Joint comfort may improve — consistent with GH's role in connective tissue synthesis.
Body composition shifts become detectable with consistent training and adequate protein — modest reductions in visceral fat and gradual increases in lean tissue. These effects are indirect (GH → IGF-1 → tissue response) and require sleep, protein, and progressive training as co-factors.
Cycling GH secretagogues is standard practice for two reasons: preventing receptor downregulation from chronic GHRH stimulation, and building in safety margins given limited long-term human data. Three cycling patterns are used depending on the compound and goals.
4–8 weeks on, followed by 2–4 weeks off. The most widely used pattern for CJC-1295 / Ipamorelin. Balances sustained benefit accumulation with adequate receptor reset time. During the off period, somatostatin tone normalizes and GHRH receptor density recovers.
2 weeks on, 2 weeks off, repeated. Used when faster desensitization is a concern or for peptides with higher receptor downregulation potential. Less total exposure but more frequent interruptions. Some practitioners prefer this pattern for extended, long-running research protocols.
Uninterrupted long-term use without cycling is appropriate only for FDA-approved therapies backed by multi-year safety data (e.g., semaglutide, tirzepatide, approved HGH formulations). Research-use CJC-1295/Ipamorelin does not have long-term continuous-use human data to support this pattern.
Don't stop abruptly: When ending a GH secretagogue cycle, consider tapering the final week rather than stopping cold. The GH axis adapts to chronic secretagogue stimulation — an abrupt stop can temporarily leave the axis in a below-baseline state as feedback systems recalibrate. Gradual dose reduction over 5–7 days at cycle end smooths this transition and reduces the chance of a noticeable "crash" in energy or sleep quality.
Timeline of reported effects based on published study data and clinical practice patterns. Individual responses vary significantly based on baseline GH/IGF-1, age, diet, sleep quality, and dosing protocol. Effects are most pronounced in individuals with below-optimal baseline GH.
Based on clinical data from Teichman 2006 (CJC-1295) and Raun 1998 (Ipamorelin), plus broader GH secretagogue literature. CJC-1295 and Ipamorelin have generally favorable tolerability profiles at research doses.
Chronically elevated IGF-1 is associated with theoretical increased cancer risk (consistent with insulin-signaling pathway research). IGF-1 should be tested at baseline and every 3 months during use, targeting the upper-normal physiological range — not supraphysiological levels. Avoid use if IGF-1 is already elevated.
GH/IGF-1 axis stimulation is contraindicated in individuals with active malignancy or a history of malignancy responsive to GH/IGF-1 stimulation. This is standard guidance across all GH secretagogue and HGH literature.
Mild water retention is common with any GH axis stimulation. It is dose-dependent and typically resolves with dose reduction. If significant edema occurs, reduce dose or pause use. Ensure adequate hydration and consider sodium management.
Chronic continuous GHRH receptor stimulation — particularly with CJC-1295 DAC — may cause receptor downregulation over time. This is the theoretical basis for cycling protocols (time off between use periods). Short-acting Mod GRF 1-29, with its discrete pulses and complete clearance between doses, is thought to minimize this risk.
All clinical data cited on this page is sourced from peer-reviewed publications. PubMed IDs and DOIs are provided for independent verification.
Third-party tested compounds from Swiss Chems — one of the most trusted research suppliers.
Affiliate link — supports MeetPeptide at no extra cost. All Swiss Chems products include third-party lab testing certificates.
Essential supplies for peptide preparation and subcutaneous administration of the CJC-1295 / Ipamorelin stack.
Affiliate links help support MeetPeptide at no extra cost to you.
More MeetPeptide research pages related to growth hormone peptides, secretagogues, and protocols.
Disclaimer: This page is for educational and informational purposes only. It is not medical advice. CJC-1295 and Ipamorelin are not FDA-approved for anti-aging, body composition improvement, or performance enhancement. CJC-1295 (with DAC) completed phase 1/2 clinical trials (Teichman 2006) but was not developed into an approved drug. These peptides may be available as research compounds or compounded medications in some jurisdictions. Always consult with a qualified healthcare provider before starting any peptide protocol.
All clinical data cited on this page is sourced from published peer-reviewed research. PubMed IDs and DOIs are provided for independent verification. Observational and preclinical data is identified as such throughout.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.